TRANS GENIC INC.
2342・Standard Market・Services
Business
Transgenic Group, Inc. is a pure holding company operating two businesses: the "Drug Discovery Support Business," which handles contract production of genetically modified mice, non-clinical studies, and clinical trial outsourcing, and the "Investment & Consulting Business," which drives new business development through M&A, business succession support, and diversified trading operations. The Drug Discovery Support Business serves pharmaceutical companies, universities, and research institutions as its main clients, providing seamless, integrated CRO services from basic exploratory research through clinical trials. The Investment & Consulting Business, centered on subsidiary TG Business Service, handles a wide range of products including electrical appliance retail, Western tableware e-commerce, information and communications equipment, auxiliary materials for double-glazed glass, printer toner, and rice bags. The company changed to its current name in February 2026 and transitioned to the TSE Standard Market.
Business Model
The Investment & Consulting Business, accounting for approximately 83% of net sales, generates stable operating profit and underpins the group's overall earnings base. Meanwhile, the Drug Discovery Support Business remains in an upfront-investment phase with continued losses, though the loss is narrowing through expansion of high-value-added outsourced testing services and fixed-cost reductions. By combining sales and profit contributions from operating companies acquired through M&A with the medium- to long-term monetization of the drug discovery CRO, the company advocates a Hybrid-type model that balances short-term stability with long-term growth.
Company Strengths
Transgenic Inc. has sequentially begun accepting contracts for short-term carcinogenicity studies using rasH2 mice, medium-term skin carcinogenicity studies, and medium-term colon carcinogenicity studies using rats, and the company's securities report explicitly states that these serve as a highly competitive alternative, both domestically and internationally, to the conventional two-year carcinogenicity study. Background data preparation and strengthened data evaluation systems have also been implemented, functioning as differentiated services.
The company has built a seamless service framework covering all stages of drug discovery within the group, from genetically modified mouse production, antibody production, and glycan analysis/synthesis to non-clinical pharmacological studies, safety studies, and contract clinical trials. The business alliance with Acel (integrated animal and cell evaluation) in July 2025 and the business alliance with Hokkaido System Science (support spanning nucleic acid drug synthesis through clinical trials) in October of the same year further expanded this framework.
The Investment and Consulting business recorded net sales of ¥10,922 million and operating profit of ¥480 million in FY2026 (ending March 2026), supporting the group's overall earnings. Since 2017, the company has brought a diverse range of operating subsidiaries under its umbrella through multiple M&A deals—covering electrical products, tableware e-commerce, information and communication equipment, insulated glass sub-materials, and rice bags, among others—and has achieved a track record of increasing operating profit by 9.3% year on year through price pass-through and improved gross margins even amid declining sales.
ENVALITH's Perspective
Performance Trend
Revenue peaked at ¥12,577 million in FY2022 (ended March 2022), then fell to ¥11,430 million in FY2023 (ended March 2023), before moving sideways at ¥13,083 million in FY2024 (ended March 2024), ¥13,005 million in FY2025 (ended March 2025), and ¥13,174 million in FY2026 (ending March 2026). Operating profit plunged sharply from ¥1,837 million in FY2022 (ended March 2022), and remained in loss or near breakeven from FY2023 through FY2025 (ended March 2025), before turning to a profit of ¥138 million in FY2026 (ending March 2026). The main driver was the drug discovery support business, whose revenue expanded 19.1% year on year to ¥2,259 million, sharply narrowing its loss (from ¥488 million in the prior period to ¥164 million in the current period). On the other hand, extraordinary losses of ¥500 million—including compensation payments related to the data falsification at the Iwata Research Institute and business restructuring losses associated with the closure of the Kobe Research Institute—weighed on results, leading to a net loss of ¥77 million, marking a third consecutive year of net losses. The external environment also remained challenging, with persistent price increases continuing to dampen consumer sentiment, which acted as a headwind for the retail segment of the investment and consulting business.
Growth Strategy
Strengthening the group's earnings base through consolidation and high-value-addition of drug discovery support sites and continued M&A in the investment and consulting business
Through the closure of Kobe Laboratory (decided in March 2026) and transfer of its functions to other sites by around December 2026, the company will reduce fixed costs in the drug discovery support business and concentrate management resources. In parallel, it is also promoting recovery of its financial base through the sale of Kobe Laboratory's fixed assets.
In addition to short-term carcinogenicity studies and mid-term skin carcinogenicity studies, the company is expanding differentiated services, including the mid-term colon carcinogenicity study using rats, contract work for which began in FY2026 (ending March 2026). Sales in the drug discovery support business are on an expanding trend, up 19.1% year on year, and the company aims to continue building up orders.
Through the business alliance with Assam Co., Ltd. in July 2025, the company is building an integrated safety and efficacy evaluation service combining animal testing and cell testing data. Through the business alliance with Hokkaido System Science in October 2025, it has established a consistent support framework spanning from synthesis to clinical trials for nucleic acid drug development, strengthening its competitiveness as a one-stop CRO (contract research organization).
The company continues to identify new quality investment targets through M&A, capturing demand for business succession and reorganization arising from successor shortages and the shrinking domestic market. Through appropriate support for existing investees and promotion of price pass-through and gross margin improvement, it plans to maintain stable profit contribution in FY2027 (ending March 2027) as well.
The company has formulated recurrence prevention measures centered on improving information sharing and organizational culture, reviewing the education system, strengthening data integrity (DI) response, and reviewing QAU (quality assurance unit) study investigation methods, and has revised its SOPs (standard operating procedures) accordingly. It is steadily implementing initiatives based on guidance and recommendations from relevant authorities and outside experts, aiming to rebuild the trust foundation of its CRO business.
Last updated: July 19, 2026